QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “Veterinary mRNA Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Veterinary mRNA Vaccines market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Veterinary mRNA Vaccines was estimated to be worth US$ 81.02 million in 2024 and is forecast to a readjusted size of US$ 35313 million by 2031 with a CAGR of 41.1% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4668761/veterinary-mrna-vaccines
Veterinary mRNA Vaccines Market Summary
Veterinary mRNA vaccines are a new generation of vaccines designed to protect animals from infectious diseases using messenger RNA (mRNA) technology. These vaccines work by delivering synthetic mRNA into animal cells, instructing them to produce specific antigens that trigger an immune response without using live pathogens. Compared to traditional vaccines, mRNA vaccines offer advantages such as faster development, adaptability to emerging diseases, and the ability to target multiple pathogens. They are being developed for livestock, poultry, and companion animals to combat diseases like avian influenza, swine fever, and canine influenza, improving animal health and food security.
According to the new market research report “Global Veterinary mRNA Vaccines Market Report 2024-2030”, published by QYResearch, the global Veterinary mRNA Vaccines market size is projected to reach USD 4.08 billion by 2034, at a CAGR of 29.7% during the forecast period.
Market Drivers:
Technological breakthroughs are driving innovation in vaccine models:
mRNA technology, validated in human COVID-19 vaccines, has been widely recognized for its effectiveness, safety, and rapid development.
Animal vaccines no longer rely on traditional attenuation and inactivation processes, enabling rapid synthesis, precise design, and high-throughput screening, significantly improving vaccine development efficiency.
Continuous advances in delivery technologies (such as LNPs) and mRNA stability technologies are accelerating the application and implementation of animal vaccines.
Animal diseases are numerous, mutate rapidly, and demand for vaccines is high:
Animal infectious diseases such as swine fever, PRRS, PED, and avian influenza frequently mutate, making it difficult for traditional vaccines to quickly adapt.
mRNA vaccines can complete candidate vaccine design and pilot production within 2–6 weeks, enabling rapid response to outbreaks or regional variants.
Some countries have included mRNA vaccines in their strategic animal disease prevention and control tools.
Short R&D cycles meet the rapid updating needs of industrial vaccines:
mRNA vaccines typically take 30–60 days from design to pilot batch production, significantly faster than protein subunit or viral vector vaccines. For vaccines requiring annual strain updates (such as avian influenza and swine flu), the mRNA platform offers a natural advantage.
Strong Multivalent Vaccine Development Capabilities:
mRNA vaccine technology allows for the integration of multiple antigen codes within a single molecule or formulation, making the development of multivalent vaccines more efficient.
This is particularly important for controlling common “mixed infection” diseases in pigs and poultry.
Global Animal Vaccine Market Expansion:
With the rise of the pet economy, the expansion of large-scale farming, and growing global awareness of animal health, the animal vaccine market is growing steadily.
The global animal vaccine market is projected to exceed $15 billion by 2030, providing greater potential for mRNA technology.
Increased Policy and Financial Support:
The U.S. Department of Agriculture (USDA), the European Union, and other countries have initiated review and guidance policies for mRNA animal vaccines.
Many governments have included mRNA vaccines in their “Next Generation Biosafety Vaccine” strategic plans and are providing R&D subsidies and fast-track trial approvals.
Driven by Cross-Border Capital and Technology Integration:
Many companies previously focused on human mRNA are entering the animal sector through joint ventures, licensing, and incubation. Emerging technologies such as synthetic biology, AI protein design, and cold chain logistics are deeply integrated with vaccine development to accelerate the maturity of the industry.
Restraint:
Core technological shortcomings remain:
mRNA modification technology (such as pseudouridine modification) and patents for efficient delivery systems are still monopolized by leading companies (such as BioNTech and Moderna), posing risks. The development of specialized adjuvants for animal vaccines is lagging, impacting immune efficacy.
Lack of cold chain storage and transportation capabilities:
mRNA vaccines require low-temperature storage and transportation at -20°C to -70°C, making it difficult to maintain cold chain integrity in decentralized livestock farming environments (especially in rural areas).
The registration review system needs improvement: Current laws and regulations have yet to detail the review standards for new vaccines such as mRNA, and the lack of animal testing data guidelines prolongs the time to market.
Limited market willingness to pay:
Vaccines for commercial animals (pigs and poultry) are highly price sensitive. Traditional inactivated vaccines cost only 0.3-1 yuan per dose, making it difficult to reduce the cost of mRNA vaccines to competitive levels in the short term.
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The Veterinary mRNA Vaccines market is segmented as below:
By Company
Merck Animal Health
Ceva Animal Health
Tiba Biotechnology
Jinyu Biotechnology
Harbin Enwei Biological Pharmaceutical
Shanghai Rnacure Biopharma
Ruipu Biotechnology
Jiangsu Synthgene Biotechnology
Genvax Technologies
Shanghai Shen Lian Biomedical
Suzhou Kerui Meide Biomedical Technology
Segment by Type
Non-replicating mRNA Vaccine
Self-amplifying mRNA Vaccine
Segment by Application
Pigs
Poultry
Ruminants
Companion Animals
Each chapter of the report provides detailed information for readers to further understand the Veterinary mRNA Vaccines market:
Chapter 1: Introduces the report scope of the Veterinary mRNA Vaccines report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2020-2031)
Chapter 2: Detailed analysis of Veterinary mRNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2020-2025)
Chapter 3: Provides the analysis of various Veterinary mRNA Vaccines market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2020-2031)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2020-2031)
Chapter 5: Sales, revenue of Veterinary mRNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2020-2031)
Chapter 6: Sales, revenue of Veterinary mRNA Vaccines in country level. It provides sigmate data by Type, and by Application for each country/region.(2020-2031)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2020-2025)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth Veterinary mRNA Vaccines competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides Veterinary mRNA Vaccines comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides Veterinary mRNA Vaccines market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global Veterinary mRNA Vaccines Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Veterinary mRNA Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Global Veterinary mRNA Vaccines Market Research Report 2025
Global Veterinary mRNA Vaccines Market Insights, Forecast to 2031
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
